SCHEMBL21564239

SCHEMBL21564239

CC(C)(C)OC(=O)NCCc1c[nH]c2ccc(-c3cccnc3)cc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.60
CDK4 P11802 1/20 0.59
CCND1 P24385 1/20 0.59
NR4A2 P43354 1/20 0.55
GAA P10253 1/20 0.55
HPGD P15428 1/20 0.52
CYP1A2 P05177 4/20 0.52
CYP3A4 P08684 4/20 0.52
CYP2D6 P10635 4/20 0.52
CYP2C19 P33261 4/20 0.52
CLK4 Q9HAZ1 4/20 0.52
USP2 O75604 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
CYP2C9 P11712 2/20 0.52
LMNA P02545 1/20 0.52
MAPK1 P28482 1/20 0.52
TRPV1 Q8NER1 3/20 0.52
FAAH O00519 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7334188 0.88 TRPV1 (0.65) IDO1CDK4CCND1TRPV1FAAH
SCHEMBL8869454 0.86 LTA4H (0.57) IDO1GAAHPGDCYP1A2CYP3A4
SCHEMBL20267062 0.85 CDK4 (0.66) CDK4CCND1NR4A2GAAHPGD
SCHEMBL7307246 0.83 FAAH (0.56) HPGDCYP1A2CYP3A4CYP2D6ALDH1A1
SCHEMBL3900495 0.82 IDO1 (0.53) IDO1GAAHPGDCYP1A2CYP3A4
SCHEMBL7315015 0.82 TRPV1 (0.57) IDO1CDK4CCND1MEN1KMT2A
SCHEMBL3891002 0.80 IDO1 (0.53) IDO1CDK4CCND1GAACYP1A2
SCHEMBL8613795 0.79 TRPV1 (0.55) IDO1HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL798165 0.79 TRPV1 (0.70) IDO1HPGDCYP1A2CYP3A4CYP2D6
SCHEMBL31077788 0.79 TRPV1 (0.70) IDO1HPGDCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 US disclosed
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 US disclosed
US-20190345143-A1 HEPARANASE INHIBITORS AND USE THEREOF Beta Therapeutics Pty Ltd (AU) 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345143-A1 HEPARANASE INHIBITORS AND USE THEREOF HPSE, HEXD, ENGASE IDO1 985/4885CDK4 2267/4885CCND1 4779/4885
US-11787783-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE IDO1 985/4885CDK4 2267/4885CCND1 4779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.